Amid swirling speculation, Bausch + Lomb ($BLCO), a global leader in the contact lens supply industry, is reportedly ...

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

including Bausch + Lomb contact lens brands such as Bausch + Lomb INFUSE®, Bausch + Lomb ULTRA® and Biotrue® ONEday. Over-the-counter products will include LUMIFY® redness reliever eye drops ...

Comfort was the name of the game when OT spoke with contact lens manufacturers and suppliers about recent trends and launches ...

Monday was an eventful day for Bausch + Lomb (NYSE: BLCO). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval.

Biotrue up 4%, Ultra up 6%, even soft lens up 3% ... and it helps support the Surgical business because Bausch + Lomb is front and center with doctors around the world, and that can help support ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

Steve Scala, an analyst from TD Cowen, maintained the Hold rating on Bausch Health Companies (BHC – Research Report). The associated ...

Good morning and welcome to Bausch + Lomb’s Third Quarter 2024 Earnings Call. [Operator Instructions] Please note this event ...